ResearcherWenzhou Medical UniversityActive in the last 2 years

Quan Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5842-8032; OpenAlex author ID A5100763933. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

A Mesoporous Silica-Based Nano-Drug Co-Delivery System with Gemcitabine for Targeted Therapy of Pancreatic Cancer. Co-author DOI 10.29271/jcpsp.2024.12.1456 ↗
Intratumour microbiome of pancreatic cancer. First author DOI 10.4251/wjgo.v15.i5.713 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shiwei Guan · 2 shared papers, 2023–2024 · strength 0.62
- Paper A Mesoporous Silica-Based Nano-Drug Co-Delivery System with Gemcitabine for Targeted Therapy of Pancreatic Cancer. DOI 10.29271/jcpsp.2024.12.1456 ↗
- Paper Intratumour microbiome of pancreatic cancer. DOI 10.4251/wjgo.v15.i5.713 ↗
Haibo Yu · 1 shared paper, 2024 · strength 0.31
- Paper A Mesoporous Silica-Based Nano-Drug Co-Delivery System with Gemcitabine for Targeted Therapy of Pancreatic Cancer. DOI 10.29271/jcpsp.2024.12.1456 ↗
Haibo Yu · 1 shared paper, 2023 · strength 0.31
- Paper Intratumour microbiome of pancreatic cancer. DOI 10.4251/wjgo.v15.i5.713 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.